A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, efanesoctocog alfa (BIVV001), in Patients With Severe Hemophilia A

Trial Identifier: EFC16293
Sponsor: Bioverativ, a Sanofi company
Start Date: November 2019
Primary Completion Date: February 2022
Study Completion Date: February 2022
Condition: Hemophilia

Trial Locations

Country Location
Argentina Buenos Aires, Argentina
Argentina Mendoza, Argentina
Australia Perth, Australia
Australia Sydney, Australia
Belgium Brussels, Belgium
Brazil Campinas, Brazil
Bulgaria Plovdiv, Bulgaria
Bulgaria Sofia, Bulgaria
Canada Hamilton, Canada
France Brest, France
France Lille, France
France Lyon, France
France Marseille, France
Germany Berlin, Germany
Germany Bonn, Germany
Germany Frankfurt, Germany
Greece Athens, Greece
Hungary Budapest, Hungary
Hungary Debrecen, Hungary
Italy Milan, Italy
Italy Vicenza, Italy
Japan Kawasaki, Japan
Japan Kitakyushu, Japan
Japan Nagoya, Japan
Japan Nara, Japan
Japan Tokyo, Japan
Mexico Durango, Mexico
Netherlands Utrecht, Netherlands
South Korea Daegu, South Korea
South Korea Seoul, South Korea
Spain Madrid, Spain
Taiwan Chang Hua, Taiwan
Taiwan Taipei, Taiwan
United Kingdom Basingstoke, United Kingdom
United Kingdom London, United Kingdom
United States, California Los Angeles, California, United States, 90027
United States, California Los Angeles, California, United States, 90007-2664
United States, California San Diego, California, United States, 92121
United States, Florida Gainesville, Florida, United States, 32610
United States, Michigan Ann Arbor, Michigan, United States, 48109
United States, Michigan Lansing, Michigan, United States, 48824
United States, Nevada Las Vegas, Nevada, United States, 89113
United States, Washington Seattle, Washington, United States, 98101-3932